The B6 compound formulation is currently available only as an injectable
Inject 0.6 mL in a single weekly injection, under the skin (subcutaneously)
by the end of 2023 at a list price of $1,059.87 for a month's supply, slightly higher than Mounjaro's $1,023.04
In its decision announced Thursday, the FDA concluded based on data from Eli Lilly, patients, providers, compounders, and other sources that "Lilly's supply is currently meeting or exceeding demand and that, based on our best judgment, it will meet or exceed projected demand." The FDA is giving so-called 503A compounding pharmacies until Feb
Advise caregivers that MOUNJARO KwikPen is not recommended for self-administration by pediatric patients or those with visual impairment unless their healthcare provider determines the patient can properly administer
Starting with a low dose can help reduce discomfort